Eifler et al reported updated Partin tables for data from 2006 to 2013 for men with clinically localized prostate cancer.
Patient selection: male with clinically localized prostate cancer
Parameters:
(1) T code from T1c to T2c
(2) serum PSA in ng/mL
(3) Gleason score
OC = organ confined
ECE = extracapsular extension
SV = seminal vesicle involvement
LN = lymph node metastases
T Code |
PSA |
GS |
OC |
ECE |
SV+ |
LN+ |
T1c |
0 to 2.5 |
6 |
93 |
7 |
0 |
0 |
|
|
3+4 |
83 |
15 |
2 |
0 |
|
|
4+3 |
80 |
17 |
3 |
0 |
|
|
8 |
79 |
18 |
3 |
0 |
|
|
9 or 10 |
74 |
20 |
5 |
2 |
|
2.6 to 4 |
6 |
87 |
12 |
0 |
0 |
|
|
3+4 |
71 |
25 |
2 |
1 |
|
|
4+3 |
65 |
28 |
4 |
3 |
|
|
8 |
65 |
28 |
4 |
3 |
|
|
9 or 10 |
56 |
29 |
7 |
8 |
|
4.1 to 6 |
6 |
84 |
15 |
1 |
0 |
|
|
3+4 |
66 |
29 |
4 |
1 |
|
|
4+3 |
60 |
31 |
6 |
3 |
|
|
8 |
59 |
32 |
6 |
3 |
|
|
9 or 10 |
50 |
32 |
10 |
8 |
|
6.1 to 10 |
6 |
80 |
18 |
1 |
0 |
|
|
3+4 |
59 |
34 |
6 |
1 |
|
|
4+3 |
53 |
35 |
9 |
3 |
|
|
8 |
52 |
36 |
9 |
3 |
|
|
9 or 10 |
42 |
36 |
9 |
3 |
|
>10 |
6 |
69 |
27 |
3 |
0 |
|
|
3+4 |
43 |
42 |
13 |
3 |
|
|
4+3 |
34 |
38 |
20 |
8 |
|
|
8 |
33 |
39 |
20 |
8 |
|
|
9 or 10 |
23 |
33 |
25 |
18 |
T2a |
0 to 2.5 |
6 |
90 |
10 |
0 |
0 |
|
|
3+4 |
76 |
22 |
2 |
0 |
|
|
4+3 |
72 |
24 |
3 |
1 |
|
|
8 |
71 |
24 |
3 |
1 |
|
|
9 or 10 |
65 |
27 |
6 |
2 |
|
2.6 to 4 |
6 |
82 |
18 |
1 |
0 |
|
|
3+4 |
61 |
34 |
3 |
1 |
|
|
4+3 |
56 |
35 |
5 |
4 |
|
|
8 |
54 |
36 |
5 |
4 |
|
|
9 or 10 |
45 |
36 |
7 |
11 |
|
4.1 to 6 |
6 |
78 |
21 |
1 |
0 |
|
|
3+4 |
56 |
38 |
4 |
2 |
|
|
4+3 |
49 |
39 |
7 |
4 |
|
|
8 |
48 |
40 |
7 |
4 |
|
|
9 or 10 |
39 |
39 |
10 |
11 |
|
6.1 to 10 |
6 |
73 |
26 |
1 |
0 |
|
|
3+4 |
48 |
44 |
6 |
1 |
|
|
4+3 |
42 |
44 |
10 |
4 |
|
|
8 |
41 |
45 |
10 |
4 |
|
|
9 or 10 |
32 |
43 |
14 |
10 |
|
>10 |
6 |
60 |
36 |
4 |
1 |
|
|
3+4 |
32 |
50 |
14 |
4 |
|
|
4+3 |
25 |
44 |
20 |
10 |
|
|
8 |
24 |
45 |
20 |
10 |
|
|
9 or 10 |
16 |
37 |
24 |
22 |
T2b/2c |
0 to 2.5 |
6 |
82 |
17 |
1 |
0 |
|
|
3+4 |
61 |
33 |
5 |
1 |
|
|
4+3 |
55 |
34 |
8 |
2 |
|
|
8 |
54 |
35 |
8 |
3 |
|
|
9 or 10 |
45 |
35 |
13 |
7 |
|
2.6 to 4 |
6 |
70 |
28 |
2 |
1 |
|
|
3+4 |
44 |
46 |
6 |
4 |
|
|
4+3 |
36 |
43 |
10 |
11 |
|
|
8 |
35 |
44 |
10 |
11 |
|
|
9 or 10 |
24 |
37 |
13 |
25 |
|
4.1 to 6 |
6 |
64 |
32 |
2 |
1 |
|
|
3+4 |
38 |
49 |
9 |
4 |
|
|
4+3 |
30 |
45 |
14 |
11 |
|
|
8 |
30 |
46 |
13 |
11 |
|
|
9 or 10 |
20 |
38 |
17 |
24 |
|
6.1 to 10 |
6 |
58 |
38 |
4 |
1 |
|
|
3+4 |
31 |
52 |
12 |
4 |
|
|
4+3 |
24 |
47 |
18 |
10 |
|
|
8 |
24 |
48 |
18 |
10 |
|
|
9 or 10 |
16 |
40 |
23 |
22 |
|
>10 |
6 |
42 |
47 |
9 |
2 |
|
|
3+4 |
17 |
50 |
23 |
9 |
|
|
4+3 |
12 |
39 |
30 |
20 |
|
|
8 |
11 |
40 |
29 |
20 |
|
|
9 or 10 |
6 |
27 |
30 |
36 |
Specialty: Hematology Oncology